Gå direkt till huvudinnehållet

Sexuell dysfunktion i menopausen

Senast uppdaterad: Publicerad:
Sakkunnig:

  1. Basson R, Berman J, Burnett A et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000; 163: 888-93. PubMed  
  2. Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause? Fertil Steril 2001; 76: 456-60. PubMed  
  3. Fugl-Meyer A, Fugl-Meyer KS. Sexual disabilities, problems and satisfaction in 18-74 year old swedes. Scand J Sexology 1999; 2: 79-106. PubMed  
  4. Castelo-Branco C, Blumel JE, Araya H et al. Prevalence of sexual dysfunction in a cohort of middle-aged women: influences of menopause and hormone replacement therapy. J Obstet Gynaecol 2003; 23: 426-30. PubMed  
  5. Köster A, Eplov LF, Garde K. Anticipations and experiences of menopause in a Danish female general population cohorte born in 1936. Arch Womens Ment Health 2002; 5: 9-13. PubMed  
  6. Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: a literature review. Menopause 2004; 11: 120-30. PubMed  
  7. Avis NE, Stellato R, Crawford S et al. Is there an association between menopause status and sexual functioning? Menopause 2000; 7: 297-309. PubMed  
  8. Løkkegaard E, Jovanovic Z, Heitmann B et al. Increased risk of stroke in hypertensive women using hormone replacement therapy. Arch Neurol 2003; 60: 1379-84. PubMed  
  9. Gregersen N, Hilmand CB, Jensen PT, Giraldi AGE. Seksuel dysfunktion i menopausen. Ugeskr Læger 2006; 168: 559-63. PubMed  
  10. Løkkegaard E, Pedersen A, Heitmann B et al. Relation between hormone replacement therapy and ischaemic heart disease in women: a prospective observational study. BMJ 2003; 326: 426-30. British Medical Journal  
  11. Writing group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288: 321-33. Journal of the American Medical Association  
  12. Nelson HD, Humphrey LL, Nygren P et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872-81. Journal of the American Medical Association  
  13. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27. PubMed  
  14. Bachmann G, Bancroft J, Braunstein G et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77: 660-5. PubMed  
  15. Basson R, McInnes R, Smith MD et al. Efficacy and safety of Sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Women's Health Gender Med 2002; 11: 367-77.
  16. Berman JR, Berman LA, Toler SM et al. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J Urol 2003; 170: 2333-8. PubMed  
  17. Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. BJOG 2003; 110: 1014-24. PubMed  
  18. Nastri CO, Lara LA, Ferriani RA, et al. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2013 Jun 5;6. PMID: 23737033. PubMed  
  19. Dennerstein L, Burrows GD, Wood C et al. Hormones and sexuality: effect of Estrogen and Progestogen. Obstet Gynecol 1980; 56: 316-22. PubMed  
  20. Nathorst-Boos J, Wiklund I, Mattsson LA et al. Is sexual life influenced by transdermal estrogen therapy? Acta Obstet Gynecol Scand 1993; 72: 656-60. PubMed  
  21. Nathorst-Boos J, Hammar M. Effect on sexual life - a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 1997; 26: 15-20. PubMed  
  22. Kokcu A, Cetinkaya MB, Yanik F et al. The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas 2000; 36: 75-80. PubMed  
  23. Wu MH, Pan HA, Wang ST et al. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric 2001; 4: 314-9. PubMed  
  24. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2003; 4. The Cochrane Library  
  25. Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 2009; 16: 719-27. PubMed  
  26. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy: sexual behavior and neuroendocrine responses. J Reprod Med 1998; 43: 847-55. PubMed  
  27. Lobo RA, Rosen RC, Yang H-M et al. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003; 79: 1341-52. PubMed  
  28. Flöter A, Nathorst-Boos J, Carlström K et al. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being. Climacteric 2002; 5: 357-65. PubMed  
  29. Shifren JL, Braunstein GD, Simon JA et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682-8. New England Journal of Medicine  
  30. Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric 2001; 4: 28-41. PubMed  
  31. Palacios S, Menendez C, Jurado AR et al. Changes in sex behaviour after menopause: effects of tibolone. Maturitas 1995; 22: 155-61. PubMed  
  32. Dennerstein L, Lehert P. Modeling mid-aged women's sexual functioning: a prospective, population-based study. J Sex Marital Ther 2004; 30: 173-83. PubMed  
  • Elsa Lena Ryding, docent och överläkare, Kvinnors och Barns Hälsa, Karolinska institutet

Tidigare sakkunniga

  • Terje Johannessen, professor i allmänmedicin, Institutt for samfunnsmedisinske fag, Norges teknisk-naturvitenskapelige universitet, Trondheim
  • Per Bergsjø, professor emeritus, med. dr., Universitetet i Bergen. Specialist i kvinnosjukdomar och förlossningshjälp, forskare vid Nasjonalt folkehelseinstitutt, Oslo